Alkermes ALKS OH Risperidone Palimate — Collaborative Arrangement Patent Royalty Rate

Similar metrics at other companies

BMYRest of World Except Japan, South Korea and Taiwan — Royalty rate due to regulatory approvals

3.8%0.0pp

BMYNorth America — Royalty rate due to regulatory approvals

1%0.0pp

IONSRoyalty Payments

$11.69M-9.3%

PTGXLicense And Service — Collaborative Agreement Profit Share Percentage

50%—

BMYSupply Agreements — Royalty Income

$300M0.0%

BAXHealthcare Systems & Technologies — Royalty rate

3%—

Questions, answered.

What is Alkermes's OH risperidone palimate — collaborative arrangement patent royalty rate?

Alkermes (ALKS) reported OH risperidone palimate — collaborative arrangement patent royalty rate of 0.4% in Q4 2025.

How has Alkermes's OH risperidone palimate — collaborative arrangement patent royalty rate changed year-over-year?

Alkermes's OH risperidone palimate — collaborative arrangement patent royalty rate decreased by 0.0% year-over-year, from 0.4% to 0.4%.

What is the long-term trend for Alkermes's OH risperidone palimate — collaborative arrangement patent royalty rate?

Over 4 years (2021 to 2025), Alkermes's OH risperidone palimate — collaborative arrangement patent royalty rate has grown at a 0.0% compound annual growth rate (CAGR), from 1.5% to 1.5%.

What does OH risperidone palimate — collaborative arrangement patent royalty rate mean?

This metric represents the percentage of net sales paid to a collaborative partner specifically for the use of patented intellectual property related to a pharmaceutical product. It reflects the cost structure associated with maintaining legal rights to manufacture and sell the drug under a licensing agreement. This rate is a critical component of the overall royalty burden on the product's gross revenue.